Dr. John Lambert, Ph.D.
Dr. John Lambert, Ph.D is one of the leading experts in the field of ADC discovery and development. He joined ImmunoGen in 1987 and served as Chief Scientific Officer from 2008 until 2015, and was subsequently Distinguished Research Fellow at ImmunoGen until retirement in 2018. During John’s tenure in leadership roles, ImmunoGen invented the antibody-drug conjugate technology that resulted in Kadcyla® (Genentech/Roche) and mirvetuximab soravtansine (ImmunoGen), for treatment of HER2+ breast cancer and platinum-resistant ovarian cancer respectively. Dr Lambert is the author/co-author of over 120 peer-reviewed scientific publications. He is a fellow of the American Institute for Medical and Biological Engineering (AIMB) and an Honorary Professor of Queen’s University, Belfast, Northern Ireland, UK.